Breaking Finance News

Zacks Investment Research reported on Exelixis, Inc. (NASDAQ:EXEL), raising its target to $28.00 earlier today

Having a price of $24.75, Exelixis, Inc. (NASDAQ:EXEL) traded 2.39% higher on the day. With the last stock price close up 18.96% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same time. The company has recorded a 50-day moving average of $26.53 and a 200-day moving average of $22.70. 2,571,397 shares of the stock were exchanged, down from an average trading volume of 4,067,440

Zacks Investment Research increased the stock price target of Exelixis, Inc. (NASDAQ:EXEL) to $28.00 stating a potential upside of 0.13%.

Recent Performance Chart

Exelixis, Inc. (NASDAQ:EXEL)

Exelixis, Inc. has 52 week low of $10.04 and a 52 week high of $28.45 with a PE ratio of 136.36 and has a market cap of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokers have issued a report on the company. The average stock price target is $7.00 with 3 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Exelixis, Inc. (NASDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.